Denali Therapeutics Inc.

Genentech, Inc.

Hoffmann-la Roche Inc.

Medical Research Council Technology

F. Hoffmann-la Roche Ag

F. Hoffmann-la Roche Sa

Anthony A Estrada

Zachary Kevin Sweeney

Jianwen A Feng

Javier De Vicente Fidalgo

Joseph P Lyssikatos

Brian M Fox

Bryan K Chan

Maksim Osipov

Daniel Shore

Huifen Chen

Snahel Patel

Charles Baker-Glenn

Michael Siu

Mark Stewart Chambers

Colin Philip Leslie

Arun Thottumkara

Cheng Hu

Alan G Olivero

Daniel J Burdick

Robert A Craig, Ii

Alfonso Pozzan

Wen Liu

Vishal Verma

Terry Kellar

Malcolm Huestis

Christopher R H Hale

Cinzia Maria Francini

Anantha R Sudhakar

Kevin X Chen

Guiling Zhao

Shumei Wang

Matthew Volgraf

Giorgio Bonanomi

Baihua Hu

Katrina W Lexa

Daniel Jon Burdick

Paul Gibbons

Travis Remarchuk

Janet L Gunzner-Toste

Zachary Sweeney

Changyou Ma

Liting Dong

Elena Serra

Yimin Qian

Sung-Sau So

Shawn David Erickson

Steven Huy Do

Aleksandr Kolesnikov

Daniel Fred Ortwine

Zhonghua Pei

Peter Michael Wovkulich

Timothy Heffron

Frederick Cohen

Allen John Lovey

Po-Wai Yuen

Shaoqing Chen

Christine E Brotherton-Pleiss

Kyungjin Kim

Elisia Villemure

Lan Wang

Hongju Li

Wen K Liu

Guosheng Wu

Cuong Q Ly

Michael F T Koehler

Aijun Lu

Jan Marik

Jennafer Dotson

Philippe Bergeron

Zhi Chen

Lin Yi

Carmela Napolitano

Guibai Liang

Edward Giles Mciver

Xingyu Lin

Federica Tonelli

Xianrui Zhao

Yanyan Chu

Kevin Hon Luen Lau

Janet Gunzner-Tate

Colin Phillip Leslie

David Shore

Kevin Chen

Janet Gunzner-Toste

Daniel John Burdick

Robert A Ii Craig

Joseph Lyssikatos

Alan Olivero

The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Compounds, compositions and methods

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or pharmaceutical composition thereof, and methods of making and using thereof.

LRRK2 inhibitors and methods of making and using thereof

The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.

The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

Kinase inhibitors and uses thereof

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

Modulators of eukaryotic initiation factor 2B, compositions and methods

The present disclosure relates generally to compounds of formula (I) or a pharmaceutically acceptable salt, prodrug, deuterated analog, tautomer, stereoisomer, or mixture of stereoisomers thereof and their use as LRRK2 inhibitors.

Substituted pyrimidines as LRKK2 inhibitors

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.

Compounds, compositions, and methods

The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators

Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds are also disclosed.

Compound, compositions, and methods

Growing community of inventors

South San Francisco, CA, United States of America

Anthony A Estrada